nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—CA14—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.039	0.326	CbGpPWpGaD
Zoledronate—GGPS1—uterine cervix—cervical cancer	0.0368	0.0613	CbGeAlD
Zoledronate—GGPS1—decidua—cervical cancer	0.0351	0.0584	CbGeAlD
Zoledronate—GGPS1—renal system—cervical cancer	0.0345	0.0573	CbGeAlD
Zoledronate—GGPS1—endometrium—cervical cancer	0.0333	0.0554	CbGeAlD
Zoledronate—CA12—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.0328	0.275	CbGpPWpGaD
Zoledronate—GGPS1—mammalian vulva—cervical cancer	0.0322	0.0536	CbGeAlD
Zoledronate—GGPS1—uterus—cervical cancer	0.0307	0.0511	CbGeAlD
Zoledronate—GGPS1—female reproductive system—cervical cancer	0.0276	0.0459	CbGeAlD
Zoledronate—GGPS1—female gonad—cervical cancer	0.0251	0.0418	CbGeAlD
Zoledronate—CA2—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.0251	0.21	CbGpPWpGaD
Zoledronate—GGPS1—vagina—cervical cancer	0.025	0.0415	CbGeAlD
Zoledronate—CA2—exocrine gland—cervical cancer	0.0204	0.034	CbGeAlD
Zoledronate—FDPS—uterine cervix—cervical cancer	0.017	0.0283	CbGeAlD
Zoledronate—Mucosal inflammation—Topotecan—cervical cancer	0.0169	0.0606	CcSEcCtD
Zoledronate—FDPS—decidua—cervical cancer	0.0162	0.0269	CbGeAlD
Zoledronate—GGPS1—lymph node—cervical cancer	0.0161	0.0269	CbGeAlD
Zoledronate—CA12—renal system—cervical cancer	0.0161	0.0267	CbGeAlD
Zoledronate—FDPS—renal system—cervical cancer	0.0159	0.0264	CbGeAlD
Zoledronate—FDPS—endometrium—cervical cancer	0.0154	0.0256	CbGeAlD
Zoledronate—FDPS—mammalian vulva—cervical cancer	0.0149	0.0247	CbGeAlD
Zoledronate—FDPS—uterus—cervical cancer	0.0142	0.0236	CbGeAlD
Zoledronate—Interstitial lung disease—Topotecan—cervical cancer	0.0132	0.0474	CcSEcCtD
Zoledronate—CA12—female reproductive system—cervical cancer	0.0129	0.0214	CbGeAlD
Zoledronate—FDPS—female reproductive system—cervical cancer	0.0127	0.0212	CbGeAlD
Zoledronate—Pleural effusion—Topotecan—cervical cancer	0.0122	0.0438	CcSEcCtD
Zoledronate—FDPS—female gonad—cervical cancer	0.0116	0.0193	CbGeAlD
Zoledronate—FDPS—vagina—cervical cancer	0.0115	0.0191	CbGeAlD
Zoledronate—Rigors—Topotecan—cervical cancer	0.0115	0.0411	CcSEcCtD
Zoledronate—FDPS—SREBP signalling—YY1—cervical cancer	0.0114	0.0955	CbGpPWpGaD
Zoledronate—ABCC1—uterine cervix—cervical cancer	0.00986	0.0164	CbGeAlD
Zoledronate—Bone pain—Topotecan—cervical cancer	0.00979	0.035	CcSEcCtD
Zoledronate—ABCC1—decidua—cervical cancer	0.0094	0.0156	CbGeAlD
Zoledronate—ABCC1—endometrium—cervical cancer	0.00892	0.0148	CbGeAlD
Zoledronate—CA2—epithelium—cervical cancer	0.00889	0.0148	CbGeAlD
Zoledronate—ABCC1—mammalian vulva—cervical cancer	0.00863	0.0144	CbGeAlD
Zoledronate—Neoplasm—Topotecan—cervical cancer	0.00848	0.0303	CcSEcCtD
Zoledronate—CA2—decidua—cervical cancer	0.0084	0.014	CbGeAlD
Zoledronate—CA2—renal system—cervical cancer	0.00825	0.0137	CbGeAlD
Zoledronate—ABCC1—uterus—cervical cancer	0.00822	0.0137	CbGeAlD
Zoledronate—CA2—mammalian vulva—cervical cancer	0.00771	0.0128	CbGeAlD
Zoledronate—FDPS—lymph node—cervical cancer	0.00744	0.0124	CbGeAlD
Zoledronate—Lethargy—Topotecan—cervical cancer	0.00694	0.0248	CcSEcCtD
Zoledronate—ABCC1—female gonad—cervical cancer	0.00672	0.0112	CbGeAlD
Zoledronate—ABCC1—vagina—cervical cancer	0.00668	0.0111	CbGeAlD
Zoledronate—CA2—female reproductive system—cervical cancer	0.00661	0.011	CbGeAlD
Zoledronate—Cramp muscle—Topotecan—cervical cancer	0.00613	0.0219	CcSEcCtD
Zoledronate—CA2—female gonad—cervical cancer	0.00601	0.01	CbGeAlD
Zoledronate—CA2—vagina—cervical cancer	0.00597	0.00994	CbGeAlD
Zoledronate—Pancytopenia—Topotecan—cervical cancer	0.00559	0.02	CcSEcCtD
Zoledronate—Neutropenia—Topotecan—cervical cancer	0.0055	0.0197	CcSEcCtD
Zoledronate—Weight increased—Topotecan—cervical cancer	0.00535	0.0191	CcSEcCtD
Zoledronate—Infestation NOS—Topotecan—cervical cancer	0.00524	0.0188	CcSEcCtD
Zoledronate—Infestation—Topotecan—cervical cancer	0.00524	0.0188	CcSEcCtD
Zoledronate—Stomatitis—Topotecan—cervical cancer	0.00511	0.0183	CcSEcCtD
Zoledronate—Hypoaesthesia—Topotecan—cervical cancer	0.00468	0.0168	CcSEcCtD
Zoledronate—ABCC1—lymph node—cervical cancer	0.00432	0.00719	CbGeAlD
Zoledronate—Angiopathy—Topotecan—cervical cancer	0.00427	0.0153	CcSEcCtD
Zoledronate—Immune system disorder—Topotecan—cervical cancer	0.00425	0.0152	CcSEcCtD
Zoledronate—Mediastinal disorder—Topotecan—cervical cancer	0.00424	0.0152	CcSEcCtD
Zoledronate—Chills—Topotecan—cervical cancer	0.00422	0.0151	CcSEcCtD
Zoledronate—Alopecia—Topotecan—cervical cancer	0.00416	0.0149	CcSEcCtD
Zoledronate—Malnutrition—Topotecan—cervical cancer	0.0041	0.0147	CcSEcCtD
Zoledronate—Back pain—Topotecan—cervical cancer	0.00396	0.0142	CcSEcCtD
Zoledronate—Muscle spasms—Topotecan—cervical cancer	0.00394	0.0141	CcSEcCtD
Zoledronate—CA2—lymph node—cervical cancer	0.00386	0.00643	CbGeAlD
Zoledronate—Ill-defined disorder—Topotecan—cervical cancer	0.0038	0.0136	CcSEcCtD
Zoledronate—Anaemia—Topotecan—cervical cancer	0.00379	0.0135	CcSEcCtD
Zoledronate—Angioedema—Topotecan—cervical cancer	0.00374	0.0134	CcSEcCtD
Zoledronate—Malaise—Topotecan—cervical cancer	0.0037	0.0132	CcSEcCtD
Zoledronate—Leukopenia—Topotecan—cervical cancer	0.00367	0.0131	CcSEcCtD
Zoledronate—Cough—Topotecan—cervical cancer	0.00358	0.0128	CcSEcCtD
Zoledronate—Arthralgia—Topotecan—cervical cancer	0.00349	0.0125	CcSEcCtD
Zoledronate—Myalgia—Topotecan—cervical cancer	0.00349	0.0125	CcSEcCtD
Zoledronate—Chest pain—Topotecan—cervical cancer	0.00349	0.0125	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00347	0.0124	CcSEcCtD
Zoledronate—Discomfort—Topotecan—cervical cancer	0.00345	0.0123	CcSEcCtD
Zoledronate—Anaphylactic shock—Topotecan—cervical cancer	0.00334	0.012	CcSEcCtD
Zoledronate—Infection—Topotecan—cervical cancer	0.00332	0.0119	CcSEcCtD
Zoledronate—Nervous system disorder—Topotecan—cervical cancer	0.00328	0.0117	CcSEcCtD
Zoledronate—Thrombocytopenia—Topotecan—cervical cancer	0.00327	0.0117	CcSEcCtD
Zoledronate—Skin disorder—Topotecan—cervical cancer	0.00325	0.0116	CcSEcCtD
Zoledronate—Hyperhidrosis—Topotecan—cervical cancer	0.00323	0.0116	CcSEcCtD
Zoledronate—Anorexia—Topotecan—cervical cancer	0.00319	0.0114	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00305	0.0109	CcSEcCtD
Zoledronate—Paraesthesia—Topotecan—cervical cancer	0.003	0.0107	CcSEcCtD
Zoledronate—Dyspnoea—Topotecan—cervical cancer	0.00298	0.0107	CcSEcCtD
Zoledronate—Dyspepsia—Topotecan—cervical cancer	0.00294	0.0105	CcSEcCtD
Zoledronate—Decreased appetite—Topotecan—cervical cancer	0.00291	0.0104	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Topotecan—cervical cancer	0.00289	0.0103	CcSEcCtD
Zoledronate—Fatigue—Topotecan—cervical cancer	0.00288	0.0103	CcSEcCtD
Zoledronate—Constipation—Topotecan—cervical cancer	0.00286	0.0102	CcSEcCtD
Zoledronate—Pain—Topotecan—cervical cancer	0.00286	0.0102	CcSEcCtD
Zoledronate—Feeling abnormal—Topotecan—cervical cancer	0.00276	0.00986	CcSEcCtD
Zoledronate—Gastrointestinal pain—Topotecan—cervical cancer	0.00274	0.00978	CcSEcCtD
Zoledronate—Urticaria—Topotecan—cervical cancer	0.00266	0.0095	CcSEcCtD
Zoledronate—Abdominal pain—Topotecan—cervical cancer	0.00264	0.00946	CcSEcCtD
Zoledronate—Body temperature increased—Topotecan—cervical cancer	0.00264	0.00946	CcSEcCtD
Zoledronate—Hypersensitivity—Topotecan—cervical cancer	0.00246	0.00881	CcSEcCtD
Zoledronate—Asthenia—Topotecan—cervical cancer	0.0024	0.00858	CcSEcCtD
Zoledronate—Pruritus—Topotecan—cervical cancer	0.00237	0.00846	CcSEcCtD
Zoledronate—Diarrhoea—Topotecan—cervical cancer	0.00229	0.00818	CcSEcCtD
Zoledronate—Dizziness—Topotecan—cervical cancer	0.00221	0.00791	CcSEcCtD
Zoledronate—FDPS—SREBP signalling—MTOR—cervical cancer	0.0022	0.0184	CbGpPWpGaD
Zoledronate—Vomiting—Topotecan—cervical cancer	0.00213	0.00761	CcSEcCtD
Zoledronate—Rash—Topotecan—cervical cancer	0.00211	0.00754	CcSEcCtD
Zoledronate—Dermatitis—Topotecan—cervical cancer	0.00211	0.00754	CcSEcCtD
Zoledronate—Headache—Topotecan—cervical cancer	0.0021	0.00749	CcSEcCtD
Zoledronate—Nausea—Topotecan—cervical cancer	0.00199	0.00711	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CA9—cervical cancer	0.00162	0.0136	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.00101	0.00847	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CA9—cervical cancer	0.000792	0.00663	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CA9—cervical cancer	0.000692	0.0058	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CA9—cervical cancer	0.000667	0.00559	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—MTHFR—cervical cancer	0.000658	0.00551	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CA9—cervical cancer	0.00051	0.00427	CbGpPWpGaD
Zoledronate—CA14—Metabolism—MTHFR—cervical cancer	0.000321	0.00269	CbGpPWpGaD
Zoledronate—ABCC1—Disease—WNT2—cervical cancer	0.000312	0.00262	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—MTHFR—cervical cancer	0.000281	0.00235	CbGpPWpGaD
Zoledronate—CA12—Metabolism—MTHFR—cervical cancer	0.000271	0.00227	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CA9—cervical cancer	0.000247	0.00207	CbGpPWpGaD
Zoledronate—ABCC1—Disease—WNT5A—cervical cancer	0.000237	0.00198	CbGpPWpGaD
Zoledronate—CA2—Metabolism—MTHFR—cervical cancer	0.000207	0.00173	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HES1—cervical cancer	0.000136	0.00114	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MTHFR—cervical cancer	0.00012	0.001	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TERT—cervical cancer	0.000119	0.001	CbGpPWpGaD
Zoledronate—ABCC1—Disease—FGFR3—cervical cancer	0.00011	0.000918	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NOTCH1—cervical cancer	0.000103	0.000861	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—MTHFR—cervical cancer	0.0001	0.00084	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MTOR—cervical cancer	7.7e-05	0.000646	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CD4—cervical cancer	7.69e-05	0.000644	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CTNNB1—cervical cancer	6.83e-05	0.000572	CbGpPWpGaD
Zoledronate—ABCC1—Disease—STAT3—cervical cancer	5.95e-05	0.000499	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EGFR—cervical cancer	5.41e-05	0.000453	CbGpPWpGaD
